Cencora, Inc. (COR)
| Market Cap | 55.35B -1.2% |
| Revenue (ttm) | 328.68B +5.9% |
| Net Income | 2.55B +50.5% |
| EPS | 13.05 +52.0% |
| Shares Out | 194.56M |
| PE Ratio | 21.79 |
| Forward PE | 15.29 |
| Dividend | $2.40 (0.84%) |
| Ex-Dividend Date | May 15, 2026 |
| Volume | 1,643,768 |
| Open | 283.28 |
| Previous Close | 281.10 |
| Day's Range | 281.11 - 288.53 |
| 52-Week Range | 244.82 - 377.54 |
| Beta | 0.59 |
| Analysts | Buy |
| Price Target | 351.00 (+23.39%) |
| Earnings Date | Aug 5, 2026 |
About COR
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company’s U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, ... [Read more]
Financial Performance
In fiscal year 2025, Cencora's revenue was $321.33 billion, an increase of 9.31% compared to the previous year's $293.96 billion. Earnings were $1.55 billion, an increase of 2.99%.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for COR stock is "Buy." The 12-month stock price target is $351.0, which is an increase of 23.39% from the latest price.
News
Cencora price target raised to $285 from $280 at BofA
BofA analyst Allen Lutz raised the firm’s price target on Cencora (COR) to $285 from $280 and keeps a Neutral rating on the shares. At the firm’s Healthcare conference last…
Cencora Launches Next-Generation Nucleus® Solution with Multi-Site Pilot Across Specialty Physician Practices
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, a global pharmaceutical solutions company, today announced a multi-site pilot of its enhanced Nucleus® inventory management solution, designed to help spec...
Cencora names Samantha Hammock as Chief Human Resources Officer
Cencora (COR) “announced that Silvana Battaglia, Executive Vice President and Chief Human Resources Officer, has announced she will retire from the company following a distinguished seven-year tenure....
Suncrete, Inc. Completes Arkansas Acquisition
Company Enhances Scale and Expands Footprint into New Markets TULSA, Okla., June 15, 2026 /PRNewswire/ -- Suncrete, Inc. (Nasdaq: RMIX) ("Suncrete" or the "Company"), a ready-mix concrete logistics an...
Cencora Announces Samantha Hammock as Chief Human Resources Officer
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that Silvana Battaglia, Executive Vice President and Chief Human Resources Officer (CHRO), has announced she will retire f...
Cencora price target lowered to $350 from $425 at Barclays
Barclays lowered the firm’s price target on Cencora (COR) to $350 from $425 and keeps an Overweight rating on the shares. The firm updated estimates and targets in the drug…
Cencora to Support U.S. Distribution of Kite's CAR T-Cell Therapies
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora today announced an agreement with Kite, a Gilead Company, to support the distribution of Kite's U.S. Food and Drug Administration (FDA)-approved CAR T-cell ...
Cencora appoints Eva Boratto as CFO
Cencora (COR) appointed Eva Boratto EVP and CFO, effective June 29. Boratto succeeds James Cleary, who will be retiring from his role as EVP and CFO as previously announced. Cleary…
Cencora backs FY26 adjusted EPS view $17.70-$17.90, consensus $17.75
06:59 EDT Cencora (COR) backs FY26 adjusted EPS view $17.70-$17.90, consensus $17.75
Cencora still sees long-term adjusted EPS growth of 10%-14%
Still sees adjusted operating income growth of 7%-10%.
Cencora Appoints Eva Boratto as Executive Vice President and Chief Financial Officer
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced Eva C. Boratto has been appointed Executive Vice President and Chief Financial Officer of the Company, effective June 29, ...
Cencora revises forecast for 2026, approves $2 billion share buyback
U.S. drug distributor Cencora on Thursday raised the lower end of its fiscal 2026 earnings forecast citing recent share repurchases, and also approved a new $2 billion stock buyback plan.
Cencora narrows FY26 adjusted EPS view to $17.70-$17.90, consensus $17.76
Previous view $17.65-$17.90. The company said it updated its FY26 financial guidance as a result of recent opportunistic share repurchases. The opportunistic share repurchases completed in May align w...
Cencora Announces Updated Fiscal Year 2026 Financial Outlook
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today updated its fiscal year 2026 financial guidance as a result of recent opportunistic share repurchases. Cencora now expects adjusted ...
Cencora Transcript: Bank of America Global Healthcare Conference 2026
Management reaffirmed confidence in full-year and long-term guidance, with EPS expected at $17.65–$17.90 and $1 billion in share repurchases planned. U.S. Healthcare Solutions growth is set to accelerate, M&A integration is progressing well, and AI-driven efficiency initiatives are underway.
Cencora price target lowered to $331 from $429 at Wells Fargo
Wells Fargo analyst Stephen Baxter lowered the firm’s price target on Cencora (COR) to $331 from $429 and keeps an Overweight rating on the shares. The firm says that the…
Cencora price target lowered to $342 from $400 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Cencora (COR) to $342 from $400 and keeps an Overweight rating on the shares.
Cencora price target lowered to $339 from $420 at Baird
Baird lowered the firm’s price target on Cencora (COR) to $339 from $420 and keeps an Outperform rating on the shares.
Cencora price target lowered to $300 from $360 at Evercore ISI
Evercore ISI lowered the firm’s price target on Cencora (COR) to $300 from $360 and keeps an Outperform rating on the shares.
Cencora price target raised to $412 from $410 at UBS
UBS raised the firm’s price target on Cencora (COR) to $412 from $410 and keeps a Buy rating on the shares.
Cencora price target lowered to $355 from $405 at Citi
Citi lowered the firm’s price target on Cencora (COR) to $355 from $405 and keeps a Buy rating on the shares. The company reported “disappointing” U.S. healthcare results in fiscal…
Cencora reports Q2 adjusted EPS $4.75, consensus $4.73
Reports Q2 revenue $78.4B, consensus $81.04B. “Cencora (COR) delivered solid results in our second quarter as our team members continued to execute to meet the needs of our customers,” said…
Cencora raises FY26 adjusted EPS view to $17.65-$17.90 from $17.45-$17.75
FY26 consensus $17.61. Sees FY26 revenue growth 4%-6% vs. 7%-9% prior, consensus $345.81B.
Cencora Earnings Call Transcript: Q2 2026
Adjusted EPS grew 7.5% and operating income rose in both core segments, despite revenue headwinds from price reductions, customer losses, and faster biosimilar conversions. Full-year EPS guidance was raised, with strong cash flow and resumed share buybacks supporting long-term growth.